newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

Clinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H2022 Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H2022 Plans to repor